Literature DB >> 28245071

Inhibition of microRNA-153 protects neurons against ischemia/reperfusion injury in an oxygen-glucose deprivation and reoxygenation cellular model by regulating Nrf2/HO-1 signaling.

Qiong Ji1,2, Jianbo Gao3, Yan Zheng4, Xueli Liu1, Qiangqiang Zhou1, Canxia Shi1, Meng Yao1, Xia Chen1.   

Abstract

MicroRNAs are emerging as critical regulators in cerebral ischemia/reperfusion injury; however, their exact roles remain poorly understood. miR-153 is reported to be a neuron-related miRNA involved in neuroprotection. In this study, we aimed to investigate the precise role of miR-153 in regulating neuron survival during cerebral ischemia/reperfusion injury using an oxygen-glucose deprivation and reoxygenation (OGD/R) cellular model. We found that miR-153 was significantly upregulated in neurons subjected to OGD/R treatment. Inhibition of miR-153 significantly attenuated OGD/R-induced injury and oxidative stress in neurons. Nuclear factor erythroid 2-related factor 2 (Nrf2) was identified as a target gene of miR-153. Inhibition of miR-153 significantly promoted the expression of Nrf2 and heme oxygenase-1 (HO-1). However, silencing of Nrf2 significantly blocked the protective effects of miR-153 inhibition. Our study indicates that the inhibition of miR-153 protects neurons against OGD/R-induced injury by regulating Nrf2/HO-1 signaling and suggests a potential therapeutic target for cerebral ischemia/reperfusion injury.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  Cerebral ischemia/reperfusion injury; HO-1; Nrf2; miR-153

Mesh:

Substances:

Year:  2017        PMID: 28245071     DOI: 10.1002/jbt.21905

Source DB:  PubMed          Journal:  J Biochem Mol Toxicol        ISSN: 1095-6670            Impact factor:   3.642


  8 in total

1.  MiR-153 regulates cardiomyocyte apoptosis by targeting Nrf2/HO-1 signaling.

Authors:  Xianting Zhu; Yuling Zhao; Wei Hou; Ling Guo
Journal:  Chromosome Res       Date:  2019-04-29       Impact factor: 5.239

Review 2.  miRNA Involvement in Cerebral Ischemia-Reperfusion Injury.

Authors:  Maria-Adriana Neag; Andrei-Otto Mitre; Codrin-Constantin Burlacu; Andreea-Ioana Inceu; Carina Mihu; Carmen-Stanca Melincovici; Marius Bichescu; Anca-Dana Buzoianu
Journal:  Front Neurosci       Date:  2022-06-10       Impact factor: 5.152

3.  Lithium promotes recovery after spinal cord injury.

Authors:  Ying-Jie Zhao; Hao Qiao; Dong-Fan Liu; Jie Li; Jia-Xi Li; Su-E Chang; Teng Lu; Feng-Tao Li; Dong Wang; Hao-Peng Li; Xi-Jing He; Fang Wang
Journal:  Neural Regen Res       Date:  2022-06       Impact factor: 5.135

Review 4.  Comprehensive overview of Nrf2-related epigenetic regulations involved in ischemia-reperfusion injury.

Authors:  Jun Zhang; Wanqian Pan; Yue Zhang; Mingyue Tan; Yunfei Yin; Yuanmei Li; Lei Zhang; Lianhua Han; Jiaxiang Bai; Tingbo Jiang; Hongxia Li
Journal:  Theranostics       Date:  2022-09-11       Impact factor: 11.600

5.  MicroRNA-135b-5p prevents oxygen-glucose deprivation and reoxygenation-induced neuronal injury through regulation of the GSK-3β/Nrf2/ARE signaling pathway.

Authors:  Qiang Duan; Wei Sun; Hua Yuan; Xiang Mu
Journal:  Arch Med Sci       Date:  2018-03-28       Impact factor: 3.318

Review 6.  Heme Oxygenase 1 in the Nervous System: Does It Favor Neuronal Cell Survival or Induce Neurodegeneration?

Authors:  Mariapaola Nitti; Sabrina Piras; Lorenzo Brondolo; Umberto Maria Marinari; Maria Adelaide Pronzato; Anna Lisa Furfaro
Journal:  Int J Mol Sci       Date:  2018-08-01       Impact factor: 5.923

7.  Crocetin alleviates myocardial ischemia/reperfusion injury by regulating inflammation and the unfolded protein response.

Authors:  Ming Yang; Genxiang Mao; Lili Ouyang; Chenhui Shi; Pengfei Hu; Shuwei Huang
Journal:  Mol Med Rep       Date:  2019-12-17       Impact factor: 2.952

8.  MicroRNA-153-3p regulates cell proliferation and cisplatin resistance via Nrf-2 in esophageal squamous cell carcinoma.

Authors:  Jing Zuo; Mei Zhao; Zhisong Fan; Bowei Liu; Yudong Wang; Yuehong Li; Ping Lv; Lingxiao Xing; Xianghong Zhang; Haitao Shen
Journal:  Thorac Cancer       Date:  2020-02-03       Impact factor: 3.500

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.